The Impact of ROS and NGF in the Gliomagenesis and their Emerging Implications in the Glioma Treatment.

NGF ROS brain cancer carcinogenesis glioma gliomagenesis. oxidative stress

Journal

CNS & neurological disorders drug targets
ISSN: 1996-3181
Titre abrégé: CNS Neurol Disord Drug Targets
Pays: United Arab Emirates
ID NLM: 101269155

Informations de publication

Date de publication:
03 Apr 2023
Historique:
received: 06 07 2022
revised: 19 12 2022
accepted: 01 02 2023
entrez: 5 4 2023
pubmed: 6 4 2023
medline: 6 4 2023
Statut: aheadofprint

Résumé

Reactive oxygen species (ROS) are highly reactive molecules derived from molecular oxygen (O2). ROS sources can be endogenous, such as cellular organelles and inflammatory cells, or exogenous, such as ionizing radiation, alcohol, food, tobacco, chemotherapeutical agents and infectious agents. Oxidative stress results in damage of several cellular structures (lipids, proteins, lipoproteins, and DNA) and is implicated in various disease states such as atherosclerosis, diabetes, cancer, neurodegeneration, and aging. A large body of studies showed that ROS plays an important role in carcinogenesis. Indeed, increased production of ROS causes accumulation in DNA damage leading to tumorigenesis. Various investigations demonstrated the involvement of ROS in gliomagenesis. The most common type of primary intracranial tumor in adults is represented by glioma. Furthermore, there is growing attention on the role of the Nerve Growth Factor (NGF) in brain tumor pathogenesis. NGF is a growth factor belonging to the family of neurotrophins. It is involved in neuronal differentiation, proliferation and survival. Studies were conducted to investigate NGF pathogenesis's role as a pro- or anti-tumoral factor in brain tumors. It has been observed that NGF can induce both differentiation and proliferation in cells. The involvement of NGF in the pathogenesis of brain tumors leads to the hypothesis of a possible implication of NGF in new therapeutic strategies. Recent studies have focused on the role of neurotrophin receptors as potential targets in glioma therapy. This review provides an updated overview of the role of ROS and NGF in gliomagenesis and their emerging role in glioma treatment.

Identifiants

pubmed: 37016521
pii: CNSNDDT-EPUB-130661
doi: 10.2174/1871527322666230403105438
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Francesca Fanfarillo (F)

Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.

Giampiero Ferraguti (G)

Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.

Marco Lucarelli (M)

Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.

Silvia Francati (S)

Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.

Christian Barbato (C)

Institute of Biochemistry and Cell Biology, IBBC-CNR, Rome, Italy.

Antonio Minni (A)

Department of Sensory Organs, Sapienza University of Rome, Italy.

Mauro Ceccanti (M)

SITAC, Società Italiana per il Trattamento dell'Alcolismo e le sue Complicanze, Rome, Italy.

Luigi Tarani (L)

Department of Maternal Infantile and Urological Sciences, Sapienza University of Rome, Italy.

Carla Petrella (C)

Institute of Biochemistry and Cell Biology, IBBC-CNR, Rome, Italy.

Marco Fiore (M)

Institute of Biochemistry and Cell Biology, IBBC-CNR, Rome, Italy.

Classifications MeSH